Trial Profile

A Phase 2 Randomized, Open-label Trial to Evaluate the Early Bactericidal Activity, Safety, Tolerability, and Dose-Response of Oral Alpibectir in Combination with Ethionamide, and with Ethionamide, Rifampicin, Pyrazinamide, and Ethambutol in Adults with Newly Diagnosed, Drug-Susceptible Pulmonary Tuberculosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpibectir (Primary) ; Ethionamide (Primary) ; Ethambutol; Pyrazinamide; Rifampicin; Rifampicin/isoniazid/pyrazinamide/ethambutol
Indications Tuberculosis
Focus Therapeutic Use
Acronyms ENABLE

26 Mar 2025 According to a BioVersys media release, first patient has been dosed in this trial. This trial is conducted under the European Union's IMI2 UNITE4TB project.
07 Mar 2025 Status changed from not yet recruiting to recruiting.
31 Dec 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com